Eli Lilly and Company (LLY), 2024 Q4 earnings digest

from Earnings Report Digest · host ValueVerge

$LLY has just released its Q4 2024 earnings report, highlighting robust revenue growth of 45% compared to Q4 2023, driven by strong performance from Mounjaro and Zepbound. Key risks include the competitive landscape in the incretin market and ongoing pricing pressures.

Episode metadata supplied by the publisher feed · Published Feb 7, 2025

Embed this episode

Attribution link and audio player

NOW PLAYING

Eli Lilly and Company (LLY), 2024 Q4 earnings digest

0:00 1:54

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Earnings Report Digest?

This episode is 1 minute long.

When was this Earnings Report Digest episode published?

This episode was published on February 7, 2025.

Can I download this Earnings Report Digest episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!